1 citations
,
June 2013 in “Annals of the Rheumatic Diseases” Methotrexate plus prednisolone had the fewest serious side effects.
1 citations
,
February 1994 in “Drug Investigation” Sulfasalazine might cause hair loss, especially in women, and stopping it can reverse the hair loss.
November 2024 in “Rheumatology Advances in Practice” Monitor for early signs of azathioprine toxicity and check blood counts regularly.
April 2012 in “Journal of the American Academy of Dermatology” Clofazimine effectively treated ashy dermatosis in a patient.
5 citations
,
January 2021 in “Inflammatory Bowel Diseases” Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
1 citations
,
March 1989 in “The BMJ” A woman's hair grew back while she was taking sulphasalazine for arthritis.
16 citations
,
April 2014 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia” A patient lost all their hair while on rheumatoid arthritis medication.
September 2013 in “Neurodegenerative disease management” Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.
41 citations
,
December 2015 in “JAMA Dermatology” Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.
1 citations
,
May 2025 in “The Journal of Rheumatology” Upadacitinib may help treat difficult cases of systemic lupus erythematosus.
October 2024 in “Internal Medicine” Stopping nalfurafine reversed hair loss in a hemodialysis patient.
51 citations
,
July 2003 in “Annals of the Rheumatic Diseases” Co-trimoxazole may help treat autoimmune diseases.
18 citations
,
November 2018 in “Annals of the Academy of Medicine Singapore” Sulfasalazine can cause severe allergic reactions leading to long-term autoimmune issues like hair loss and skin discoloration.
7 citations
,
July 1990 in “Journal of the American Academy of Dermatology” A woman with bullous pemphigoid had an allergic reaction to azathioprine, but got better with alternative treatments.
January 2024 in “Journal of Crohn's and colitis” Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.
72 citations
,
November 2015 in “Multiple Sclerosis and Related Disorders” Teriflunomide is safe and tolerable for treating relapsing-remitting multiple sclerosis, with manageable side effects.
5 citations
,
November 2023 in “The Journal of Dermatology” Anifrolumab effectively improved symptoms and reduced steroid use in Japanese patients with systemic lupus erythematosus.
March 2024 in “Poster presentations” Anifrolumab improves quality of life and reduces steroid use in SLE patients.
January 2021 in “Anais do Congresso Brasileiro de Reumatologia 2020” Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.
29 citations
,
January 2016 in “CNS drugs” Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.
Mycophenolate mofetil is a good alternative for autoimmune hepatitis patients who can't tolerate azathioprine.
January 2025 in “Journal of Crohn s and Colitis” Tofacitinib is effective and safe for elderly patients with ulcerative colitis.
20 citations
,
December 2016 in “Neurodegenerative disease management” Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.
April 2015 in “Reactions Weekly” Some elderly men had healing problems after using imiquimod and diclofenac for skin conditions on their scalps.
January 2008 in “Zhonghua linchuang mianyi he biantai fanying zazhi” The treatment with Shunyou and prednisone is effective and safe for lupus nephritis.
Anifrolumab improves quality of life and reduces steroid use in lupus patients.
30 citations
,
September 2005 in “Best Practice & Research Clinical Rheumatology” The document concludes that treating tough skin disease in lupus involves sun protection, steroids, antimalarials, and various other therapies chosen based on individual risks and benefits.
1 citations
,
July 2019 in “Clinical Rheumatology” Leflunomide is more likely to help treat alopecia areata than cause it.
May 2025 in “International Journal of Science and Research (IJSR)” Stopping azathioprine led to full hair regrowth and recovery in 2.5 months.
2 citations
,
April 2019 in “Dermatologic Therapy” A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.